ArticleFrontiers in microbiology2025
Jiawei Buyang Huanwu Decoction modulates gut microbiota and metabolic profiles in a rat model of idiopathic pulmonary fibrosis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Bridging the gaps: the gut-lung axis and microbial metabolites in the pathogenesis and treatment of pulmonary fibrosis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with irreversible fibrosis and poor prognosis. Jiawei Buyang Huanwu Decoction (JBHD) has demonstrated therapeutic effects, but the exact mechanisms, particularly those mediated by the gut microbiota, remain largely unexplored. This study aimed to explore how JBHD modulates gut microbiota, and how these changes may influence host metabolic regulation in the context of IPF. Methods: The IPF model was established via intratracheal bleomycin injection. After 28 days of treatment, feces samples were obtained for 16S rRNA gene sequencing, whereas serum and urine samples were collected for metabolomic analyses. Results: Gut microbiota analysis showed that JBHD restored microbial dysbiosis in IPF rats. Differentially altered fecal microbes (DAFMs) reversed by JBHD included Discussion: JBHD may act by reshaping specific microbial communities, which in turn could help restore related metabolic disturbances. These findings suggest a possible microbiota-mediated mechanism through which JBHD may exert its effects along the gut-lung axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.